Ono Pharma Submits a Supplemental Application in Japan to Expand the Use of VELEXBRU® Tablets for the Treatment of Central Nervous System Involvement of Malignant Lymphoma in Patients with Inadequate Response to Existing Therapies or in Whom Such Therapies Are Not Appropriate

Ono Pharma Submits a Supplemental Application in Japan to Expand the Use of OPDIVO for the Treatment of Unresectable Anaplastic Thyroid Cancer

Bristol Myers Squibb Announces OPDIVO® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma

Ono Pharma Announces Oral Presentation of New Data from Phase 2 Clinical Study of ONO-4578 (EP4 antagonist) in Certain Gastric Cancers at the ASCO 2026 Annual Meeting

Ono Pharma Announces Poster Presentation of New Clinical Data from Phase 2 Study of ONO-2808 (S1P5 Receptor Agonist) in Multiple System Atrophy at the 7th World Parkinson Congress (WPC)